Artrya (AYA) FDA Announcement summary

Introduction and purpose

• FDA 510(k) clearance granted for Salix Coronary Anatomy, enabling entry into the U.S. market and immediate commercialization.

• Regulatory approvals now held in the U.K., Europe, Australia, New Zealand, and the USA.

• Salix offers a point-of-care approach for coronary artery disease assessment, the first major advancement in 50 years.

• Focus shifts to commercializing in the U.S., expanding partnerships, and leveraging hospital relationships for rapid market penetration.

Details of approval or decision

• FDA clearance allows immediate sales cycle initiation and commercial sale in the U.S., starting with established hospital partnerships.

• Salix Coronary Anatomy will be launched across 15 hospitals, outpatient centers, and heart and vascular centers in the U.S. Southeast.

• FDA clearance provides a platform for future products, with Salix Coronary Anatomy as the predicate device.

• Approval differentiates the product with a point-of-care, rapid (10-minute) assessment capability.

• Enables seamless integration of upcoming products (SCP and SCF) into the existing platform.

Impact on industry and stakeholders

• U.S. partners (Tanner, Northeast Georgia, Cone) to begin commercial integration, with more hospital systems in discussion and expansion anticipated in 2025.

• Enables proactive, non-invasive coronary artery disease assessment within 10 minutes of a CCTA scan, improving workflow and reducing costs.

• U.S. market size estimated at 4.4 million CCTA scans/year, growing at over 6% per year, with significant growth potential.

• High demand in the U.S. has led to pipeline management to ensure quality delivery.

• Continued market traction targeted in Australia, focusing on top radiology providers, though revenue impact is minor compared to the U.S.